Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.

Item
http://www.wikidata.org/entity/Q38126936
Marine Sponges as a Drug TreasureBioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemiaPharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential.Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance.Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.Protein kinase inhibitors for acute leukemia.Chemotherapy-induced differential cell cycle arrest in B cell lymphomas affects their sensitivity to Wee1 inhibition.
P2860

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.

Item
http://www.wikidata.org/entity/Q38126936
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
@en
type
label
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
@en
prefLabel
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932